

BOROSIL®**Borosil Limited**

CIN : L36100MH2010PLC292722

Registered & Corporate Office :

1101, Crescenzo, G-Block, Opp. MCA Club, Bandra Kurla Complex,

Bandra (E), Mumbai - 400 051, India.

T +91 22 6740 6300

F +91 22 6740 6514

E borosil@borosil.com

W www.borosil.com

May 09, 2022

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543212	National Stock Exchange of India Limited Exchange Plaza, C-1, Block – G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Symbol: BOROLTD
---	---

Dear Sirs,

Sub : Intimation of Analysts/ Institutional Investors Conference Call and Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the Company, as part of its investors engagement activities is planning to have a conference call with the Institutional Investors and Analysts on **Wednesday, May 11, 2022 at 11.00 a.m.**, to discuss its performance for the quarter and year ended March 31, 2022.


Please find attached the following:

- Invitation for the Investors Conference Call; and
- Presentation on the performance of the Company for the quarter and year ended March 31, 2022.

These are also being uploaded on the Company's website at www.borosil.com.

You are requested to take note of the same.

Thanking you.

Yours faithfully,
For **Borosil Limited**
Anshu Agarwal
Company Secretary & Compliance Officer
FCS-9921

Encl: As above



Q4FY22 Results Conference Call

We co-ordially invite you for a call with the management of Borosil Ltd to discuss its performance for the quarter and year ended 31st March 2022.

Con Call date: Wednesday, 11th May 2022, at 11:00 AM IST

Represented by:

Mr. Shreevar Kheruka - Managing Director & CEO

Mr. Rajesh Kumar Chaudhary - Whole Time Director

Mr. Anand Sultania - Chief Financial Officer

Mr. Swadhin Padia - General Manager - Accounts

Dial In Details:

Conference Dial-In:	
Universal DialIn	Primary access number: +91 22 6280 1326 Secondary access number: +91 22 7115 8227
Toll Free Number	Hong Kong: 800964448
	Singapore: 8001012045
	UK: 08081011573
	USA: 18667462133
International Toll Number	Hong Kong: +852 30186877
	Singapore: +65 31575746
	UK: +44 2034785524
	USA: +1 3233868721

Diamond Pass registration link:

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1995719&linkSecurityString=89608c5c2>

For further information please contact:

Praveen Sahay

Edelweiss Broking Ltd.

Tel.: +91 (22) 6187 9611

E-mail: praveen.sahay@edelweissfin.com



Borosil Limited

Investor Presentation Q4FY22



BOROSIL®



“ This investor presentation has been prepared by Borosil Limited (“Borosil” or “Company”) on a strictly confidential basis. Certain statements in this presentation may be ‘forward looking statements’ within the meaning of applicable laws and regulations. These forward looking statements reflect our intentions, plans, expectations, assumptions, and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside our control. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. Important developments that could affect the company’s operations include change in the industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. The company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward looking statements to reflect subsequent events or circumstances. this presentation cannot be copied and disseminated in any manner. No person is authorized to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorized by or on behalf of Borosil. This should not be construed as an offer to sell or the solicitation of an offer to buy any securities or fresh issuance of any securities of the company”



Brand with a 50+ year legacy



Enjoys strong consumer equity in serving-ware, kitchen appliances and storage



National leader in laboratory glassware



■ ■ ■ **To be the most customer-centric company in India**



Offer products that perform beautifully



Develop innovative products to meet evolving customer needs





Be a dependable partner that creates value for customers





Nurture long-term relationships with all stakeholders







SALESCAGR : **18%****Operating
EBITDA**CAGR : **26%**

The figures are in INR Crore

INR Crore

	Q4FY20	Q4 FY21	Q4 FY22	Growth %
Net Sales	141.8	184.1	220.1	19.6%
EBITDA	(3.1)	37.9	39.6	4.6%
EBITDA (Before exceptional items)	(3.1)	37.9	44.4	17.1%
EBITDA (%)	(2.2)%	20.6%	20.2%	
EBIT (Before exceptional items)	(12.5)	28.6	36.4	27.5%
PBT	(13.7)	27.9	31.1	11.5%
PAT	(10.6)	18.4	34.6	87.6%
Net Cash (Period end)	72	246	235	



INR Crore

	FY20	FY21	FY22	Growth %
Net Sales	635.9	584.8	839.9	43.6%
EBITDA	87.4	99.1	157.0	58.3%
EBITDA (Before exceptional items)	87.4	102.7	168.2	63.7%
EBITDA (%)	13.7%	17.6%	20.0%	
EBIT (Before exceptional items)	49.1	67.3	134.3	99.7%
PBT	43.6	61.2	122.0	99.2%
PAT	35.3	42.4	85.2	101.2%
Net Cash (Period end)	72	246	235	





INR Crore

	Q4 FY20	Q4 FY21	Q4 FY22	Growth %
Net Sales	86.4	118.1	137.5	16.5%
EBITDA	(6.7)	19.6	17.2	(12.2)%
EBITDA (Before exceptional items)	(6.7)	19.6	19.6	(0.1)%
EBITDA (%)	(7.8)%	16.6%	14.3%	
EBIT (Before exceptional items)	(11.8)	13.6	14.2	4.4%
PBT	(12.4)	13.3	11.6	(12.9)%





				INR Crore
	FY20	FY21	FY22	Growth %
Net Sales	434.0	384.8	573.0	48.9%
EBITDA	53.6	47.7	88.6	85.8%
EBITDA (Before exceptional items)	53.6	49.5	94.2	90.4%
EBITDA (%)	12.4%	12.9%	16.4%	
EBIT (Before exceptional items)	29.5	27.0	71.5	165.1%
PBT	26.7	24.0	65.4	172.7%



INR Crore

Category	Q 4 FY21	Q 4 FY22	Growth %	FY21	FY22	Growth %
Glassware	30.3	37.2	22.9%	102.6	146.0	42.3%
Non Glassware	36.0	50.0	38.8%	141.1	207.4	47.0%
Opalware	51.8	50.3	(2.9)%	141.1	219.6	55.7%
Total Consumerware	118.1	137.5	16.5%	384.8	573.0	48.9%





INR Crore

	Q4 FY20	Q4 FY21	Q4 FY22	Growth %
Net Sales	55.4	66.0	82.6	25.1%
EBITDA	5.5	16.1	20.4	26.5%
EBITDA (Before exceptional items)	5.5	16.1	22.8	41.2%
EBITDA (%)	10.0%	24.4%	27.6%	
EBIT (Before exceptional items)	1.2	12.8	20.1	58.0%
PBT	0.6	12.4	17.5	40.9%





	INR Crore			
	FY20	FY21	FY22	Growth %
Net Sales	201.8	200.0	266.9	33.4%
EBITDA	32.0	42.2	54.7	29.8%
EBITDA (Before exceptional items)	32.0	44.0	60.4	37.3%
EBITDA (%)	15.9%	22.0%	22.6%	
EBIT (Before exceptional items)	17.9	31.0	49.2	58.7%
PBT	15.1	28.0	43.0	53.8%



INR Crore

Category	Q 4 FY21	Q 4 FY22	Growth %	FY21	FY22	Growth %
Laboratory Glassware	44.3	52.4	18.3%	126.5	156.2	23.4%
Lab Instrumentation	5.7	7.9	38.6%	15.9	21.3	33.6%
Pharma Packaging	16.0	22.2	39.1%	57.5	89.5	55.5%
Total Scientific	66.0	82.6	25.1%	200.0	266.9	33.4%



INR Crore

	FY 21	FY 22
Shareholders' Funds	707.62	783.25
<i>Less : Intangible Assets (Goodwill)</i>	<i>(67.67)</i>	<i>(67.67)</i>
Tangible Net Worth	639.95	715.58
<i>Add : Deffered Tax Liability</i>	<i>11.49</i>	<i>18.63</i>
<i>Add : Total Debt</i>	<i>7.27</i>	<i>0.00</i>
Capital Employed	658.71	734.21
<i>Less : Investments</i>	<i>(245.19)</i>	<i>(223.15)</i>
Operating Capital Employed	413.52	511.06
PBT (Before Exceptional Items)	61.24	133.22
<i>Less : Income from Investments</i>	<i>(9.38)</i>	<i>(13.65)</i>
<i>Add : Finance Cost</i>	<i>2.42</i>	<i>1.12</i>
EBIT (Before Investment Income)	54.28	120.69
Operational ROCE (Annualized)	13.1%	23.6%

Note : Capital employed = Tangible Net Worth + Total Debt + Deferred Tax Liability

INR Crore

	Consumerware		Scientific		Borosil	
	FY 21	FY 22	FY 21	FY 22	FY 21	FY 22
Working Capital Employed	58.8	92.7	58.7	79.2	117.5	171.9
Working Capital (Days of Sale)	56	59	107	108	73	75
Operating Capital Employed	230.6	297.8	182.9	213.2	413.5	511.0
Operational ROCE	11.7%	24.0%	16.9%	23.0%	14.0%	23.6%



Both businesses already run as separate profit centers with largely differentiated teams



Both businesses have different capital and operating requirements



Different organic and inorganic growth potential and capital raising requirements




Each business has a different investor profile



Few functions may remain under common services eg. legal, secretarial, and HR

Steps for making effective composite scheme of arrangement

Activity	Expected Timeline
Board approval of the companies involved in the Scheme	Completed
Submission of Scheme along with supporting documents to BSE & NSE	Completed
BSE & NSE shall issue an Observation Letter / NOC after incorporating comments of SEBI	June 2022
File company applications along with the Scheme to NCLT	July 2022
NCLT to pass order for holding / dispensing with the meetings of equity shareholders / creditors of the companies	August 2022
Meetings of shareholders / creditors to be held for seeking their approval to the Scheme	August 2022
Companies to send the scheme to be sent to RD, RoC, OL, Income Tax authorities, inviting their objections if any	October 2022
Final hearing of petition and approval of NCLT	December 2022
File certified copy of NCLT Order with RoC to make the scheme effective	December 2022
Stock Exchanges to issue listing and trading approval for equity shares of Borosil Scientific Limited	February 2023



- Borosil Limited ('BL' or 'Demerged Company') (listed on BSE and NSE).
- Klass Pack Limited ('KPL' or Resulting Company / Transferee Company') is a 82.49% subsidiary of BL.
- Borosil Technologies Limited ('BTL' or 'Transferor Company') is a 100% subsidiary of BL.





- It is proposed to demerge SIP business of BL into KPL and in consideration KPL will issue equity shares to the shareholders of BL and shall get listed on BSE and NSE.
- The present investment of BL i.e. 82.49% in KPL will be cancelled.
- As a part of the scheme BTL will get merged with KPL.
- KPL will be renamed as Borosil Scientific Limited and will carry on all the scientific and industrial products business. (i.e. its present business + SIP division of BL + BTL business)



Expanding from being synonymous with microwavable glass to storage, serving-ware, and domestic appliances

PREPARE**COOK****SERVE****HEAT****STORE**

- **Contemporary**
- **Everyday Use**
- **Performs Beautifully**
- **Ally to the progressive homemaker**



Category	Market Size - Branded (Cr.)	Market Growth %
Glass Microwavables	230	10%
Tumblers	520	10%
Storage	700	15% to 20%
Insulated Bottle Range	1100	10%
Opalware	900	15% to 20%
Tea / Coffee	400 (Incl ceramicware)	15%
Domestic Appliances	9000	10%



- Estimated market share of microwavables is 60%
- Tumblers universe consists of Borosilicate glass & Soda Lime glass, Borosil primarily markets Borosilicate Glasses.
- Opportunity to convert from plastic to glass in opalware & storage

Note : Market size, growth & share are internal estimates



Made in India

- Enhance/ build manufacturing capacity for Opal Glass and Borosilicate Glass



New product development



To promote Borosil glassware for daily use




To make glassware affordable for mass consumers







Borosil Consumer Profile:

- Progressive Homemaker
- SEC A1-A2
- Urban Metro, Mini Metros, A & B Cities
- Age Group : 25-45









#2 player in approx. INR 900 cr category

- Gained share

Focus on market expansion

- Healthier, economic and aesthetic alternative to melamine or steel
- Microwavable, light, break-resistant, non-porous, stain proof, bone ash free

Adoption being led by

- Urbanization and nuclearization of families
- Increase in entertaining guests at home

Capacity expansion

- Enhance furnace capacity to 84 TPD
- Increase pressware and spinning ware capacity
- Target Implementation by Q2 FY23





Indian kitchen storage dominated by plastic and steel

- Very low penetration of glass storage



Awareness of glass as a superior option on the rise

- No health hazard as in some types of plastic
- Transparent as against opaque steel & plastic getting stained and translucent over time
- Looks as good as new for extended period of time
- Good design ensures stack-ability & space optimization



High grade steel design for on-the-go products like flasks & hot food cases an opportunity





- Large market with growth accelerated post Covid
- Opportunity to create a high quality mass premium range leveraging the Borosil brand
- Commenced without investments in manufacturing assets
- Expanding range of product offerings
- Increase Made in India portfolio and reduce dependence of China supply chain





Achieve revenue CAGR of more than 20%

- Increase penetration of glass storage and Opalware
- Introduce high-quality & innovative To-Go storage products
- Gain share in premium niche domestic appliances
- Accelerate growth in E-commerce



Become brand of consumer choice

- Maintain investments in brand building
- Introduce new and improved range of products
- Benchmark online consumer experience with best-in-class



Improve EBITDA margins

- Improve logistics cost
- Rationalise packaging costs
- Control fixed overheads



Optimise capital employed

- Better estimation of channel inventories
- Increase share of domestic sourcing
- Digital Transformation Initiatives





Laboratory Glassware

- Volumetric flasks
- Burettes
- Pipettes
- Liquid handling systems



Lab Instrumentation

- Magnetic Stirrer
- Block Digester
- Multi-Tube Vortexer



Pharma Packaging

- Glass Vials
- Glass Ampoules



	Lab Glassware India	Lab Glassware Exports	Lab Instrumentation	Pharma Packaging (Vials & Ampoules)
Market size (INR Cr.)	250	4000	570	1175
Estimated market growth	~8-10%	~2-3%	~8-10%	~10-12%
Customers	Pharma R&D & QC, Government Labs, Food and Soil testing, Educational institutes	Pharma R&D, QC	Pharma R&D & QC, Government Labs, Food and Soil testing, Educational institutes	Pharma companies
Brand	Borosil	Borosil	LabQuest by Borosil	Klasspack

Note : Market size, growth & share are internal estimates





Made in India


- Build manufacturing capacity for raw material - tubing production



New product development



Substantially enhance capacity for ampoules and vials production





Cipla



Mylan®
Seeing
is believing™



LUPIN



DR. REDDY'S



RANBAXY



ALKEM



Incepta




glenmark
A new way for a new world



Zydus



TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD.



**Achieve revenue CAGR of ~15%**

- Maintain dominant share in pharma lab glassware
- Build export market in Lab Glassware & pharma packaging
- Drive import substitution in Lab Instrumentation - increase product range
- Add new customers & products in vials & ampoules

**Maintain EBITDA margins**

- Manage changing portfolio composition

**Cash Flow Efficiency**

- Manage receivables
- Manage inventories with scale





Meeting wide product range need of customer

- Single supplier convenient for laboratory for multiple critical yet low priced SKUs
- Not easily replicable by competition
- Reliable supplier for right quality at competitive cost
- Expansion into customized lab glassware, bottles & analytical vials



Quick on-time delivery of SKU range

- Investment in inventory, 5 warehouses & pan-India network of 150 dealers
- Well managed inventory more than offsets loss of sale
- Unmatched Service - 96% same-day delivery



Products meet international quality benchmarks

- Introducing new products to service emerging needs of quality and testing laboratories



Strong Customer Relationships

- Low propensity of customer to switch
- Business Partner through knowledge sharing and customization for specialized products





Portfolio of Lab Essentials, Nutrition & Environment, Life Sciences, analytical Chemistry



Leverage existing reach among pharma customers with new products in their existing workflow



Build technological advantage through Borosil Technologies with focus on Nutrition, Environment & Process Sciences



Grow distribution network



Enhance After Sales Service capabilities





Glass ampoules & tubular glass vials for packaging pharmaceutical products



Applications: Packaging of injectable formulations, ophthalmic, dental products, sample carrier for analytical instruments



Provides Borosil's pharmaceuticals customers credible second alternative for their packaging needs



Long Lead times to pass stringent quality benchmarks, a significant barrier to more entrants



New Product Opportunities in Pre-filled syringes, cartridges & siliconized vials






Export Opportunity across Asia & Europe



ESG for us is about how we create profits. It is outcome driven and not just good intentions.



Various ESG issues in current context

	 Environment	 Social	 Governance
Investors	<ul style="list-style-type: none"> - Emissions - Water - Energy 	<ul style="list-style-type: none"> - Employee health and safety - Labour practices - Customer relation 	<ul style="list-style-type: none"> - Risk management system - Code of conduct
Customers	<ul style="list-style-type: none"> - Emissions - Water - Energy - Packaging 	<ul style="list-style-type: none"> - Health and safety - Community relation - Human rights 	<ul style="list-style-type: none"> - Risk management - Code of conduct
Suppliers	<ul style="list-style-type: none"> - Waste - Energy 	<ul style="list-style-type: none"> - Employee health & safety - Customer relationship - Supplier relationship 	<ul style="list-style-type: none"> - Board Structure - Code of conduct
Employees	<ul style="list-style-type: none"> - Emissions - Water - Energy 	<ul style="list-style-type: none"> - Employee health & safety - Community relationship 	<ul style="list-style-type: none"> - Risk management - Code of conduct

Our analysis of our stakeholders

Borosil Limited is on a transformational journey to address key ESG opportunities and create long term value for our customers.

Our strategic ESG priorities		Our actions in FY22
<ul style="list-style-type: none"> - Aim to achieve Carbon neutral operations - Create a positive water balance - Explore waste management opportunities - Transition to low carbon energy 	 <p>Green planet</p>	<ul style="list-style-type: none"> - Plans to undertake GHG monitoring and inventorization to track emissions - Using recyclable corrugated packaging and limit use of thermocol packaging - Exploring on-site solar capabilities and renewable energy procurement
<ul style="list-style-type: none"> - Achieve a zero-accident workplace - Become an equal opportunity employer - Integrate suppliers as business partners - Building resilient communities - Empowering customers 	 <p>Social equity</p>	<ul style="list-style-type: none"> - Achieved zero fatality year on year - Launch an equal opportunity policy by FY2023 - Company wide strategic supply chain management program to be launched - Multiple community development programs launched on need basis - Highly customer focused operations with special grievance redressal department for customers
<ul style="list-style-type: none"> - Focusing on highest ethical standards - Creating a risk management framework - Creating a strong IT infrastructure 	 <p>Robust governance</p>	<ul style="list-style-type: none"> - A group wide code of conduct applicable to all employees and leadership. Plans in place to launch mandatory training - ESG risks are incorporated in the risk management framework - A group-wide program on evaluation of IT risks

BL aims to disclose quantifiable targets in short to medium term and transparently report performance against the targets.



Pradeep Kumar Kheruka
Chairman



Shreevar Kheruka
Vice Chairman & M.D & CEO



Rajesh Kumar Chaudhary
Whole Time Director



Anupa Rajeev Sahney
Independent Director



Kewal Kundanlal Handa
Independent Director




Kanwar Bir Singh Anand
Independent Director



Naveen Kumar Kshatriya
Independent Director

No. of Shares issued of Re. 1 each: 11,41,62,667

Share holding pattern



Bloomberg Ticker :

1369812D:IN

NSE Ticker :

BOROLTD

BSE Ticker :

543212

**Market Capitalization
as on - 31 Mar 2022 :**

INR 3783 Cr



Company's Address

Borosil Limited
1101, Crescenzo, G - Block,
Opposite MCA Club,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051,
India.



Company's Website

www.borosil.com
www.myborosil.com



Investor Relations

Anand Sultania, Chief Financial Officer
anand.sultania@borosil.com

Thank You

